<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900783</url>
  </required_header>
  <id_info>
    <org_study_id>INH-FV1-005</org_study_id>
    <secondary_id>INH-FV1-005-PK</secondary_id>
    <secondary_id>INH-FV1-005-VR</secondary_id>
    <secondary_id>INH-FV1-AGE</secondary_id>
    <nct_id>NCT00900783</nct_id>
  </id_info>
  <brief_title>A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster</brief_title>
  <official_title>A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir in Patients With Herpes Zoster</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of two doses of FV-100 to&#xD;
      valacyclovir in patients with herpes zoster, or shingles. FV-100 has shown to be very potent&#xD;
      in cells infected with varicella zoster virus, the virus that causes shingles. The study&#xD;
      objectives include:&#xD;
&#xD;
        -  Compare the safety of FV-100 to valacyclovir&#xD;
&#xD;
        -  Compare the effect of FV-100, as compared to valacyclovir, on shingles pain&#xD;
&#xD;
        -  Compare the effect of FV-100, as compared to valacyclovir, on shingles lesions&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Herpes zoster associated pain, as measured by the Zoster Brief Pain INventory (ZBPI)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Herpes zoster associated pain</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Herpes zoster lesion healing</measure>
    <time_frame>Until healed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Routine clinical labs</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Herpes Zoster</condition>
  <condition>Shingles</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FV-100, 400 mg once daily AND valacyclovir placebo, three times a day, for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valacyclovir, 1 gram, three times a day AND FV-100 placebo, once daily, for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FV-100, 200 mg once daily AND valacyclovir placebo, three times a day, for seven days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valacyclovir</intervention_name>
    <description>1 gram, three times a day for seven days</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Valtrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FV-100</intervention_name>
    <description>400 mg, once daily, for seven days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FV-100</intervention_name>
    <description>200 mg, once daily, for seven days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir placebo</intervention_name>
    <description>three times a day, for seven days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FV-100 placebo</intervention_name>
    <description>once daily, for seven days</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women ≥ 50 years of age&#xD;
&#xD;
          -  Patients with a clinical diagnosis of HZ as evidenced by a unilateral dermatomal rash&#xD;
&#xD;
          -  Patients with zoster-related pain (ZBPI worst pain score &gt; 0)&#xD;
&#xD;
          -  Patients able to be enrolled into the study ≤ 72 hours from appearance of rash (i.e.,&#xD;
             lesions or vesicles)&#xD;
&#xD;
          -  Patients providing written informed consent&#xD;
&#xD;
          -  Patients who are able to complete all study visits per protocol&#xD;
&#xD;
          -  Men and premenopausal women must agree to practice a barrier method of birth control&#xD;
             plus the use of a spermicide for one month after the last dose of study drug (oral&#xD;
             contraceptives are not permitted)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Patients with multidermatomal or disseminated HZ (i.e., &gt; 20 vesicles beyond the&#xD;
             dermatomes adjacent to the primarily involved dermatome)&#xD;
&#xD;
          -  Patients with HZ ophthalmicus, defined as cutaneous lesions in the dermatome&#xD;
             associated with the ophthalmic division of the trigeminal nerve&#xD;
&#xD;
          -  Patients with history of impaired renal function, (e.g., calculated creatinine&#xD;
             clearance &lt;50 mL/min/1.73 m2)&#xD;
&#xD;
          -  Patients taking narcotic analgesic routinely for a chronic pain condition&#xD;
&#xD;
          -  Patients taking tricyclic antidepressants&#xD;
&#xD;
          -  Patients who have received systemic antivirals with activity against VZV within the&#xD;
             past 30 days, or a topical antiviral to treat their current HZ&#xD;
&#xD;
          -  Patients who are immunosuppressed from:&#xD;
&#xD;
               -  disease (e.g., malignancy [present or remission &lt; 5 years], HIV)&#xD;
&#xD;
               -  corticosteroid use (except intermittent or topical/inhaled beclomethasone&#xD;
                  dipropionate or equivalent &lt; 800 mcg/day), or&#xD;
&#xD;
               -  other immunosuppressive/cytotoxic therapy (cancer chemotherapy or organ&#xD;
                  transplantation)&#xD;
&#xD;
          -  Patients with gastrointestinal dysfunction that could interfere with drug absorption&#xD;
&#xD;
          -  Patients with any other condition (e.g., extensive psoriasis, chronic pain syndrome,&#xD;
             cognitive impairment) that, in the opinion of the site investigator, might interfere&#xD;
             with the evaluations required by the study&#xD;
&#xD;
          -  Patients who are not ambulatory (bed-ridden or homebound); hospitalized patients may&#xD;
             be enrolled if they are ambulatory and able to complete the study requirements&#xD;
&#xD;
          -  Patients with history of allergy to valacyclovir hydrochloride&#xD;
&#xD;
          -  Patients unlikely to adhere to protocol follow-up&#xD;
&#xD;
          -  14. Subjects taking strong CYP3A4-inhibiting protease inhibitors (specifically&#xD;
             including atazanavir, indinavir, nelfinavir, saquinavir, and ritonavir), strong CYP3A4&#xD;
             inhibitors (specifically including clarithromycin, itraconazole, ketoconazole,&#xD;
             nefazodone, telithromycin) and all strong CYP3A4 inducers (specifically including&#xD;
             rifampin, efavirenz, etravirine, phenobarbital, phenytoin, and carbamazepine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>May 12, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <disposition_first_submitted>September 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 12, 2015</disposition_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>herpes zoster</keyword>
  <keyword>shingles</keyword>
  <keyword>Phase II</keyword>
  <keyword>FV-100</keyword>
  <keyword>Inhibitex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

